Legal status · United States
Is Empagliflozin legal in the United States?
Written by Aaron CuhaReviewed Sep 2026
Direct answer
Yes. Empagliflozin is an approved medicine in the United States, classified as "FDA-approved, prescription only". Approval covers its labeled indication and it is supplied on prescription, not over the counter. Products labeled "research use only" fall outside that approval and the label does not make human use lawful. On the evidence, 4 human studies are cited on its profile.
Empagliflozin in the United States at a glance
| Classification | FDA-approved, prescription only |
|---|---|
| Note | Taking it to slow ageing is off label. No regulator anywhere has reviewed an ageing indication for this drug. |
| FDA approval status | FDA approved for type 2 diabetes, for reducing cardiovascular death in adults with type 2 diabetes and established cardiovascular disease, for heart failure across the ejection fraction range, and for chronic kidney disease. Not approved for ageing, longevity or healthspan. |
| Human studies cited | 4 of 6 citations on the profile |
| Reviewed | Sep 2026 |
Classification and note come from the Empagliflozin profile, checked against U.S. Food and Drug Administration (FDA) listings at the reviewed date.
What this means
- 01
FDA has approved Empagliflozin for at least one labeled indication, so a pharmaceutical-grade product exists in the United States and is dispensed on prescription.
- 02
Approval is indication-specific. Uses outside the label are a clinical decision for a prescriber, not something the approval itself authorizes.
- 03
Unlicensed online vials, including those labeled "research use only", are not the approved product and are not covered by the approval.
What Empagliflozin is
Four randomised outcome trials in more than 23,000 people, including a 32 percent relative reduction in all-cause death in EMPA-REG OUTCOME. The entire ageing case is one single-laboratory mouse study reporting 5.9 percent longer median survival in males, and the Interventions Testing Program has never tested this drug.
Empagliflozin blocks the kidney transporter that reabsorbs filtered glucose, so glucose and the sodium travelling with it leave in the urine. It was licensed as a diabetes drug and then turned out to do something its mechanism did not obviously predict, which is reduce cardiovascular death, heart failure hospitalisation and kidney disease progression, including in people without diabetes.
Mechanism: Selectively inhibits sodium-glucose cotransporter 2 in the proximal tubule, so filtered glucose is excreted rather than reabsorbed. The cardiorenal benefit is larger and faster than glucose lowering alone explains and is not fully accounted for.
Regulatory history: FDA approved for type 2 diabetes, for reducing cardiovascular death in adults with type 2 diabetes and established cardiovascular disease, for heart failure across the ejection fraction range, and for chronic kidney disease. Not approved for ageing, longevity or healthspan.
How FDA treats this kind of product
Approves prescription drugs by indication and polices unapproved products, including peptides sold online. Compounding pharmacies may prepare some compounds under a prescription when the FDA places them on a permitted bulk-substances category.
The classification above is the The Longevity Archive reading of U.S. Food and Drug Administration listings for Empagliflozin at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
Empagliflozin in other countries
Frequently asked questions
Is Empagliflozin legal in the United States?
Yes. Empagliflozin is an approved medicine in the United States, classified as "FDA-approved, prescription only". Approval covers its labeled indication and it is supplied on prescription, not over the counter. Products labeled "research use only" fall outside that approval and the label does not make human use lawful. On the evidence, 4 human studies are cited on its profile. Note: Taking it to slow ageing is off label. No regulator anywhere has reviewed an ageing indication for this drug.
Can I buy Empagliflozin in the United States?
Only with a prescription. Empagliflozin is classified as "FDA-approved, prescription only" in the United States, so it is dispensed by pharmacies against a prescription for its approved indication. Buying it from unlicensed online sellers or as a "research chemical" is outside that system and carries no regulatory protection. Note: Taking it to slow ageing is off label. No regulator anywhere has reviewed an ageing indication for this drug.
Is Empagliflozin FDA approved?
Yes. FDA status: FDA approved for type 2 diabetes, for reducing cardiovascular death in adults with type 2 diabetes and established cardiovascular disease, for heart failure across the ejection fraction range, and for chronic kidney disease. Not approved for ageing, longevity or healthspan.. Current US classification: "FDA-approved, prescription only". On the evidence, 4 human studies are cited on its profile.
Related compounds in the United States
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for Empagliflozin live on its compound profile.
Empagliflozin profileThis page is general information about the regulatory status of Empagliflozin in the United States, current as of Sep 2026. It is not legal advice, and classifications change; check U.S. Food and Drug Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.